We appreciate Carter's review of our article ([@r1]) and his further clarification of the chemistry across this class of compounds. In the "Results" of our article, we specifically noted the use of *ortho*-phthalates (DBP and DEP), which were often found to be used in combination with the phthalate polymers he discussed in his letter \[cellulose acetate phthalate (CAP), hypromellose phthalate (HMP), and polyvinyl acetate phthalate (PVAP)\]. We believe that we appropriately distinguished the difference between the *ortho*-phthalates and the polymers, specifically noting that the polymers have "no known toxicity."
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